Suven Pharmaceuticals Limited
Suven Pharmaceuticals Limited, a prominent player in the pharmaceutical industry, is headquartered in Hyderabad, India. Founded in 1989, the company has established itself as a leader in the development of innovative drug discovery and development services, particularly in the fields of central nervous system disorders and other therapeutic areas. With a strong focus on research and development, Suven Pharmaceuticals offers a diverse portfolio of products, including proprietary drug candidates and contract research services. The company is recognised for its unique approach to drug development, leveraging advanced technologies to enhance therapeutic efficacy. Suven's commitment to quality and innovation has positioned it favourably in the global market, earning accolades for its contributions to healthcare and significant milestones in clinical research. As it continues to expand its operational footprint, Suven Pharmaceuticals remains dedicated to improving patient outcomes through cutting-edge pharmaceutical solutions.
DitchCarbon Score
How does Suven Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Suven Pharmaceuticals Limited's score of 44 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Suven Pharmaceuticals Limited's reported carbon emissions
In 2024, Suven Pharmaceuticals Limited reported total carbon emissions of approximately 41,183,000 kg CO2e for Scope 1 and about 22,941,000 kg CO2e for Scope 2. This represents a significant commitment to reducing their carbon footprint, with a target of achieving a 15% reduction in CO2 emissions per metric ton produced for both Scope 1 and Scope 2 emissions by 2025. In 2023, the company’s emissions were higher, with Scope 1 emissions at about 48,594,000 kg CO2e and Scope 2 emissions at approximately 33,723,000 kg CO2e. The trend indicates a proactive approach towards emission management, as they aim to lower their intensity of emissions relative to production. Suven Pharmaceuticals has also committed to long-term climate goals, including a net-zero target across all scopes by 2050. This commitment aligns with industry standards and reflects their dedication to sustainable practices within the pharmaceutical sector. Overall, Suven Pharmaceuticals Limited is actively working towards reducing its carbon emissions and enhancing its sustainability profile, demonstrating a clear commitment to environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 47,497,790 | 00,000,000 | 00,000,000 |
| Scope 2 | 35,462,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Suven Pharmaceuticals Limited is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
